GLS-5300

BIOLOGICAL2 trials

Sponsors

GeneOne Life Science, Inc.

Conditions

Healthy

Phase 1

Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers

CompletedNCT02670187

GeneOne Life Science, Inc.Healthy

Start: 2016-02-29End: 2017-09-30Updated: 2019-01-09

Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers

CompletedNCT03721718

GeneOne Life Science, Inc.Healthy

Start: 2018-08-28End: 2020-04-22Updated: 2020-05-27

Related Papers

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.

2020-12-24202 citations

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.

2019-07-24227 citations